Affiliation:
1. Chulalongkorn University Faculty of Medicine
2. NorthShore University Health System
Abstract
Abstract
Detection of circulating tumor DNA (ctDNA) from plasma cell free DNA (cfDNA) has shown promise for diagnosis, therapeutic targeting, and prognosis. This study explores ctDNA detection by next generation sequencing (NGS) and associated clinicopathologic factors in patients with pancreatic adenocarcinoma (PDAC). Patients undergoing surgical exploration or resection of pancreatic lesions were enrolled with informed consent. Plasma samples (4–6 ml) were collected prior to surgery and cell free DNA was recovered from 95 of 96 plasma samples. Adequate cfDNA was obtained from 81 patients which underwent next-generation sequencing using the Oncomine Lung cfDNA assay on the Ion Torrent S5 sequencing platform. Twenty-five patients (26.3%) had detectable mutations in KRAS or TP53 with allele frequencies ranging from 0.05–8.5%. Detectable ctDNA mutations were more frequent in patients with poorly differentiated tumors, and patients without detectable ctDNA mutations showed longer survival (medians of 10.5 months vs. 18 months, p = 0.019). The detection of circulating tumor DNA in pancreatic adenocarcinomas is correlated with worse survival outcomes.
Publisher
Research Square Platform LLC
Reference29 articles.
1. Cancer statistics, 2020;Siegel RL;CA Cancer J Clin,2020
2. Popiela T, Sierzeg M. Temporal Trends in Pancreatic Cancer. Pancreat Cancer - Clin Manag. 2012;(March 2012).
3. Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol [Internet]. 2019;16(1):11–26. Available from: http://dx.doi.org/10.1038/s41571-018-0112-1
4. The Cancer Genome Atlas Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell [Internet]. 2017;32(2):185–203.e13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28810144
5. TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer;Cicenas J;Cancers (Basel),2017